Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Fig. 1

Kaplan Meier curves for overall survival (a) and progression-free survival (b) according to pre-treatment Fasting plasma glucose (FPG) in the whole cohort (n = 170). Patients with FPG ≥7 mmol/L had significantly shorter median OS and PFS compared with patients with FPG < 7 mmol/L. Abbreviations: Overall Survival (OS), Progression Free Survival (PFS)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us